Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (ATOM)

EPS Corporation

Status and phase: Completed; Phase 2

Conditions: Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer

Treatments: Drug: 5-FU; Drug: Cetuximab; Drug: l-LV; Drug: Bevacizumab; Drug: L-OHP

Study type: Interventional

Funder types: Other

Identifiers

NCT01836653

ATOM

UMIN000010209 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.

Full description

Description: The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.

Enrollment: 122 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histopathologically confirmed colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer.

2. RAS wild type

3. Synchronous* or metachronous liver limited meitastasis with no extrahepatic desiease

   • shychronous liver limited metastasis with primary lesion less than two thirds of the circumference
   • patients with primary lesion more than two thirds of the circumference can be enrolled after primary resection

4. Patients who has one or more lesion(s) of diameter 1 cm or larger (RECEST v1.1) be able to assess continuously on the basis of the protocol by contrast enhanced CT or contrast enhanced MRI of the liver:

(1)Liver metastases 5 or more (2)Liver metastases with 5 cm or larger in greatest dimension (3)Unresectable considering remaining hepatic function (4)Invasion into all hepatic veins or inferior vena cava (5)Invasion into both right and left hepatic arteries or portal veins 5.No prior chemotherapy for colorectal cancer including hepatic arterial infusion. Excluding postoperative and preoperative chemoradiotherapy except for rectal cancer with synchronous liver metastases. Patients received postoperative chemotherapy containing oxaliplatin have to be enrolled after 24 weeks from the last oxaliplatin administration.

6.No previous treatment including ablation therapy, cryotherapy and chemotherapy for metastases 7.Age at enrollment is >=20 and =<80 years 8.The Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 9.Life expectancy from the day of enrollment is 3 months or longer 10.Major organ functions less than 14 days prior to entry meet the following criteria.

1. Neu >= 1500/mm3
2. Pt >= 10.0x10^4/mm3
3. Hb >= 9.0 g/dL
4. T-bil =< 2.0 mg/dL
5. AST and ALT =< 200 IU/L
6. sCr =< 1.20 mg/dL
7. INR < 1.5
8. Proteinuria =< 2+ 11.Written informed consent

Exclusion criteria

1. Previously experienced severe allergic reaction to drugs
2. Receiving anti-platelet drugs (aspirin >= 325 mg/day) or NSAIDs
3. Receiving chronic systemic corticosteroid treatment
4. Surgery/ biopsy with skin incision or traumatic injury with suture less than 14 days prior to entry. Excluding, suture for implanted venous reservoirs with catherter is allowed.
5. Severe postoperative complications (e.g. postoperative infection, anastomic dehiscence or paralytic ileus)
6. Diagnosed as hereditary colorectal cancer
7. Active other malignancies
8. Cerebrovascular disease or symptoms less than 1 year prior to entry
9. Pleural effusion, ascites or cardiac effusion requiring drainage
10. Hemorrhage/bleeding, paralytic ileus, obstruction or ulceration of gastrointestinal tract
11. Perforation of gastrointestinal tract less than 1 year prior to entry
12. Presence of active infection
13. HBs antigen or HCV antibody positive
14. Uncontrolled comorbidity including hypertension, diabetes, arrhythmia, or other diseases (such as cardiac disorder, interstitial pneumonia or renal disorder)
15. Presence of >= grade 2 diarrhea
16. Presence of >= grade 1 peripheral neuropathy
17. Pregnant or lactating women. Women and men with childbearing potential unwilling to use effective means of contraception
18. Psychosis or psychiatric symptoms who are not able to comply with the protocol
19. Any other medical conditions disable to comply with the protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

122 participants in 2 patient groups

mFOLFOX + Bmab

Experimental group

Description:

mFOLFOX plus bevacizumab

Treatment:

Drug: 5-FU

Drug: L-OHP

Drug: Bevacizumab

Drug: l-LV

Drug: 5-FU

mFOLFOX + Cmab

Active Comparator group

Description:

mFOLFOX plus cetuximab

Treatment:

Drug: 5-FU

Drug: L-OHP

Drug: l-LV

Drug: 5-FU

Drug: Cetuximab